PI Industries Ltd

PI Industries Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from Wednesday, July 1, 2026, until 48 hours after the company's unaudited standalone and consolidated financial results for the quarter ending June 30, 2026, are made public. The exact date for the declaration of these financial results will be communicated separately. This measure is standard practice to prevent potential insider trading ahead of financial disclosures.

PI Industries Limited has approved the conversion of its unlisted, unsecured Optionally Fully Convertible Debentures (OFCDs) worth ₹70,000 million (₹700 crore) held in its wholly-owned subsidiary, PI Health Sciences Limited (PIHS), into equity shares. The conversion involves 72,46,37,687 equity shares of face value ₹70 each, at a fair value of ₹73.80 per share. This transaction does not involve cash consideration or share swap by PI Industries and will not alter the ownership or control of PIHS. The conversion is in accordance with the terms of issuance and is expected to strengthen the consolidated balance sheet of the company and its subsidiaries. PIHS operates in the Pharma-Contract Research Development and Manufacturing Organisation (CRDMO) sector.

PI Industries Limited announced on June 23, 2026, that its Board of Directors has approved the conversion of Unlisted, Unsecured Optionally Fully Convertible Debentures (OFCDs) worth ₹70,000,000,000 (₹700 Crores) held in its wholly-owned subsidiary, PI Health Sciences Limited (PIHS), into equity shares. The conversion will result in PIHS issuing 72,46,37,687 equity shares of face value ₹70.00 each, at a fair value of ₹73.80 per share. This transaction does not involve cash consideration or share swap by PI Industries and will not alter its ownership or control of PIHS. The conversion is in accordance with the terms of issuance and is expected to strengthen the consolidated balance sheet of the company and its subsidiaries. PIHS operates in the Pharma-Contract Research Development and Manufacturing Organisation (CRDMO) sector.

ICICI Prudential Mutual Fund increased its shareholding in PI Industries Ltd. by acquiring 30,90,753 shares between October 1, 2025, and May 20, 2026. This acquisition raised the fund's total holding to 1,08,58,536 shares, representing 7.157% of the company's equity. The fund clarified that these acquisitions are for investment purposes and not aimed at gaining control of PI Industries.

PI Industries Ltd has re-appointed M/s K.G. Goyal & Co. as Cost Auditors for the financial year 2026-27, based on the recommendation of the Audit Committee. The re-appointment and the remuneration of the Cost Auditors are subject to ratification by the Members at the ensuing Annual General Meeting (AGM). This decision was made during the Board of Directors meeting held on May 19, 2026.

PI Industries Ltd. has authorized Key Managerial Personnel (KMP) to determine the materiality of events and information, as per Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The authorized KMPs include Dr. Atul Kumar Gupta (Whole-Time Director), Mr. Sanjay Agarwal (Group Chief Financial Officer and Head - Strategy and Integrated Development Cell), and Ms. Shruti Joshi (Company Secretary and Compliance Officer).

PI Industries Ltd. announced changes in management, including the resignation of Mr. Rajnish Sarna as Joint Managing Director, effective May 19, 2026. He will continue as a Non-Executive, Non-Independent Director. The board also designated Ms. Lisa J Brown as the Lead Independent Director and Dr. Marco Busch as Senior Management Personnel. Additionally, Mr. Arvind Singhal will retire at the upcoming AGM, and several directors are proposed for re-appointment, subject to member approval.

PI Industries Ltd. announced key board decisions on May 19, 2026. Mr. Rajnish Sarna resigned as Joint Managing Director but will continue as a Non-Executive, Non-Independent Director. Ms. Lisa J Brown was designated as the Lead Independent Director. Mr. Arvind Singhal will retire at the upcoming AGM. Dr. Marco Busch is designated as Senior Management Personnel. The board also recommended a final dividend of ₹70 per share and approved the re-appointment of cost auditors and several directors, subject to member approval at the AGM.

The Board of Directors of PI Industries Ltd, in its meeting on May 19, 2026, recommended a final dividend of ₹10 per share (1000%) on equity shares with a face value of Re. 1/- each for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). Including an interim dividend of ₹5 per share, the total dividend for the year amounts to ₹15 per share. The dividend will be paid within 30 days of declaration at the AGM.

PI Industries Ltd. announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of ₹70 per share (7000% on face value of Re. 1 per share) for FY26, subject to shareholder approval. Including an interim dividend of ₹5, the total dividend for the year amounts to ₹75 per share. The board also approved the re-appointment of M/s K.G. Goyal & Co. as Cost Auditors for FY27. Other key decisions included management changes and re-appointments, including the resignation of Mr. Rajnish Sarna as Joint Managing Director and the appointment of Dr. Marco Busch as Senior Management Personnel.